Complete Filing Data
Acurx Pharmaceuticals, Inc. reported Net Income Loss of -$7.97 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Acurx Pharmaceuticals, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income * | -$8.0M | -$14.1M | -$14.6M | -$12.1M | -$12.7M | -$4.6M |
| Research And Development Expense | $1.8M | $5.4M | $6.0M | $4.8M | $2.0M | $2.2M |
| Operating Expenses | $8.1M | $14.1M | $14.6M | $12.1M | $12.8M | $4.6M |
| General And Administrative Expense | $6.3M | $8.7M | $8.5M | $7.3M | $10.8M | $2.4M |
| Operating Income Loss | -$8.1M | -$14.1M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$2.0M | -$2.2M | -$2.1M | -$2.8M | -$4.1M | -$4.4M | -$3.1M | -$3.4M | -$2.9M | -$3.5M | -$2.6M | -$2.7M | -$4.6M | -$4.0M | -$1.5M | -$1.3M | -$913.4K | -$1.3M |
| Research And Development Expense | $429.7K | $524.2K | $598.8K | $1.2M | $1.8M | $1.6M | $1.3M | $1.7M | $1.0M | $1.6M | $911.7K | $818.9K | $1.1M | $95.1K | $91.9K | $660.0K | $400.7K | |
| Operating Expenses | $2.0M | $2.3M | $2.1M | $2.8M | $4.1M | $4.4M | $3.1M | $3.4M | $2.9M | $3.5M | $2.6M | $2.7M | $4.6M | $4.1M | $1.5M | $1.3M | $913.4K | |
| General And Administrative Expense | $1.6M | $1.7M | $1.6M | $1.6M | $2.3M | $2.8M | $1.8M | $1.7M | $1.9M | $2.0M | $1.7M | $1.9M | $3.5M | $4.0M | $1.4M | $654.6K | $512.6K | |
| Operating Income Loss | -$2.0M | -$2.3M | -$2.8M | -$4.1M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $5.3M | $615.1K | $4.7M | $7.3M | $12.4M | $2.7M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $7.6M | $3.7M | $7.5M | $9.1M | $13.0M | $3.2M | $2.5M |
| Retained Earnings Accumulated Deficit | -$75.3M | -$67.3M | -$53.2M | -$38.6M | -$26.5M | -$13.8M | |
| Liabilities Current | $2.4M | $3.2M | $3.0M | $2.1M | $843.9K | $472.6K | |
| Liabilities And Stockholders Equity | $7.7M | $3.9M | $7.7M | $9.4M | $13.3M | $3.2M | |
| Liabilities | $2.4M | $3.2M | $3.0M | $2.1M | $843.9K | $522.4K | |
| Cash | |||||||
| Accounts Payable And Accrued Liabilities Current | $2.4M | $3.2M | $3.0M | $2.1M | $843.9K | $455.9K | |
| Common Stock Value | $2.3K | $852.00 | $14.5K | $11.6K | $10.2K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $3.8M | -$3.8M | -$1.6M | -$3.8M | $9.8M | ||
| Members Equity And Stockholders Equity | $819.9K | ||||||
| Assets | $7.7M | $3.9M | $7.7M | $9.4M | $13.3M | $3.2M | |
| Assets Current | |||||||
| Accounts And Other Receivables Net Current | $48.4K | $51.1K | $129.2K | ||||
| Non Cash Financing Activities Of Warrants Issued In Connection With Offerings | $171.4K | $618.0K | $23.2K | ||||
| Cash And Cash Equivalents At Carrying Value | |||||||
| Issuance Of Shares Of Common Stock At Market Offering | 6.4M | ||||||
| Cash And Cash Equivalents Period Increase Decrease | $9.8M | $692.1K | |||||
| Sharebased Compensation To Settle Accrued Compensation | $413.1K | ||||||
| Issuance Of Shares Of Common Stock Equity Line Of Credit Purchase Agreement | 3.8M | ||||||
| Adjustments To Additional Paid In Capital Sharebased Compensation To Settle Accrued Compensation | $413.1K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $3.6M | $3.6M | $2.3M | $2.7M | $3.4M | $6.0M | $3.9M | $6.2M | $5.3M | $9.8M | $8.8M | $10.7M | $14.3M | $15.5M | $2.5M | |||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $5.9M | $6.1M | $4.6M | $5.8M | $6.4M | $8.9M | $7.1M | $9.1M | $7.2M | $10.6M | $9.1M | $11.1M | $14.5M | $17.1M | $2.6M | |||||||||
| Retained Earnings Accumulated Deficit | -$73.7M | -$71.7M | -$69.5M | -$64.5M | -$61.7M | -$57.6M | -$48.1M | -$45.0M | -$41.5M | -$35.4M | -$31.8M | -$29.2M | -$23.9M | -$19.3M | ||||||||||
| Liabilities Current | $2.5M | $2.6M | $2.5M | $3.3M | $3.2M | $3.1M | $3.2M | $3.0M | $2.1M | $1.2M | $473.9K | $633.0K | $712.4K | $1.9M | ||||||||||
| Liabilities And Stockholders Equity | $6.1M | $6.2M | $4.8M | $6.0M | $6.6M | $9.1M | $7.2M | $9.2M | $7.4M | $10.9M | $9.3M | $11.3M | $15.0M | $17.4M | ||||||||||
| Liabilities | $2.5M | $2.6M | $2.5M | $3.3M | $3.2M | $3.1M | $3.2M | $3.0M | $2.1M | $1.2M | $473.9K | $633.0K | $712.4K | $1.9M | ||||||||||
| Cash | $14.5M | $17.1M | $3.2M | $3.4M | $2.0M | $2.5M | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | $2.5M | $2.6M | $2.5M | $3.3M | $3.2M | $3.1M | $3.2M | $3.0M | $2.1M | $1.2M | $473.9K | $633.0K | $712.4K | $1.9M | ||||||||||
| Common Stock Value | $1.8K | $1.5K | $22.4K | $16.8K | $16.0K | $15.8K | $13.0K | $13.0K | $11.7K | $11.6K | $10.3K | $10.3K | $10.1K | $9.9K | ||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $937.2K | $1.4M | -$1.9M | -$1.9M | -$547.1K | |||||||||||||||||||
| Members Equity And Stockholders Equity | $8.8M | $10.7M | $12.4M | $14.3M | $15.5M | $2.5M | $2.7M | $1.3M | $539.6K | $1.1M | ||||||||||||||
| Assets | $6.1M | $6.6M | $9.1M | $9.3M | $11.3M | $15.0M | $17.4M | |||||||||||||||||
| Assets Current | $6.2M | $4.8M | $3.9M | $6.0M | $7.7M | $7.2M | $9.2M | $7.4M | $9.4M | $10.9M | $9.2M | $13.3M | ||||||||||||
| Accounts And Other Receivables Net Current | $40.2K | $40.2K | $97.4K | $51.1K | ||||||||||||||||||||
| Non Cash Financing Activities Of Warrants Issued In Connection With Offerings | ||||||||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | $14.5M | $17.1M | $3.2M | $3.4M | $2.0M | $2.5M | ||||||||||||||||||
| Issuance Of Shares Of Common Stock At Market Offering | 1.6M | 320.2K | 4.3M | |||||||||||||||||||||
| Cash And Cash Equivalents Period Increase Decrease | ||||||||||||||||||||||||
| Sharebased Compensation To Settle Accrued Compensation | $413.1K | |||||||||||||||||||||||
| Issuance Of Shares Of Common Stock Equity Line Of Credit Purchase Agreement | 1.7M | 610.3K | ||||||||||||||||||||||
| Adjustments To Additional Paid In Capital Sharebased Compensation To Settle Accrued Compensation | $413.1K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $1.2M | $2.6M | $3.2M | $2.9M | $5.2M | $695.8K |
| Net Cash Provided By Used In Operating Activities | -$6.8M | -$10.4M | -$9.8M | -$7.5M | -$5.0M | -$3.4M |
| Increase Decrease In Prepaid Expense | -$15.1K | -$5.7K | -$159.2K | -$30.3K | $246.7K | $506.00 |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$408.8K | $200.4K | $980.8K | $1.2M | $388.0K | -$800.7K |
| Payments Of Stock Issuance Costs | $2.0M | $529.8K | $2.5M | $51.4K | ||
| Net Cash Provided By Used In Financing Activities | $10.6M | $6.6M | $8.2M | $3.7M | $14.8M | $4.0M |
| Increase Decrease In Accounts And Other Receivables | -$2.7K | -$78.0K | $129.2K | |||
| Proceeds From Issuance Of Warrants | $73.00 | $13.00 | ||||
| Proceeds From Issuance Initial Public Offering | $14.8M | |||||
| Proceeds From Warrant Exercises | $1.4M | $210.2K | $2.2M | |||
| Proceeds From Issuance Of Common Stock | $3.7M | |||||
| Proceeds From Paycheck Protection Program Loan Cares Act | $66.5K | |||||
| Proceeds From March2025Registered Direct Offering Net Of Issuance Costs | $889.4K | |||||
| Proceeds From January2025Registered Direct Offering Net Of Issuance Costs | $2.1M | |||||
| Proceeds From Issuance Of Private Placement Net Of Issuance Costs | $4.0M | |||||
| Proceeds From Issuance Of Common Stock In Connection With Equity Line Of Credit Net | $3.8M | |||||
| Proceeds From At Market Offering Net Of Issuance Costs | $6.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q2 2023 | Q1 2023 | Q3 2022 | Q1 2022 | Q2 2021 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Based Compensation | $333.6K | $894.5K | $733.5K | $761.1K | $191.7K | ||||||
| Net Cash Provided By Used In Operating Activities | -$2.1M | -$3.1M | -$1.9M | -$1.9M | -$547.1K | ||||||
| Increase Decrease In Prepaid Expense | $61.5K | $82.1K | -$58.4K | -$55.9K | $305.0K | ||||||
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$335.7K | $67.8K | $12.3K | -$210.9K | -$11.8K | ||||||
| Payments Of Stock Issuance Costs | $51.5K | $10.6K | $135.7K | $456.3K | $529.8K | $2.4M | $2.5M | $51.4K | |||
| Net Cash Provided By Used In Financing Activities | $3.0M | $4.5M | |||||||||
| Increase Decrease In Accounts And Other Receivables | -$51.1K | -$129.2K | |||||||||
| Proceeds From Issuance Of Warrants | |||||||||||
| Proceeds From Issuance Initial Public Offering | |||||||||||
| Proceeds From Warrant Exercises | $210.2K | ||||||||||
| Proceeds From Issuance Of Common Stock | $3.5M | $3.7M | |||||||||
| Proceeds From Paycheck Protection Program Loan Cares Act | |||||||||||
| Proceeds From March2025Registered Direct Offering Net Of Issuance Costs | |||||||||||
| Proceeds From January2025Registered Direct Offering Net Of Issuance Costs | |||||||||||
| Proceeds From Issuance Of Private Placement Net Of Issuance Costs | |||||||||||
| Proceeds From Issuance Of Common Stock In Connection With Equity Line Of Credit Net | |||||||||||
| Proceeds From At Market Offering Net Of Issuance Costs |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Diluted EPS * | -$5.32 | -$17.45 | -$1.15 | -$1.12 | -$1.49 | -$0.74 |
| Weighted Average Number Of Shares Outstanding Basic | 1.5M | 808.2K | 12.7M | 10.8M | 8.5M | 6.2M |
| Weighted Average Number Of Diluted Shares Outstanding | 1.5M | 808.2K | 12.7M | 10.8M | 8.5M | 6.2M |
| Earnings Per Share Basic | $-5.32 | $-17.45 | $-1.15 | $-1.12 | $-1.49 | $-0.74 |
| Common Stock Shares Authorized | 250.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 2.3M | 851.5K | 14.5M | 11.6M | 10.2M | |
| Common Stock Shares Issued | 2.3M | 851.5K | 14.5M | 11.6M | 10.2M | |
| Weighted Average Number Of Share Outstanding Basic And Diluted | ||||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | |||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$1.23 | -$1.89 | -$0.11 | -$3.45 | -$5.21 | -$0.28 | -$0.24 | -$0.28 | -$0.25 | -$0.32 | -$0.26 | -$0.26 | -$0.46 | -$0.57 | -$0.21 | -$0.21 | -$0.15 |
| Weighted Average Number Of Shares Outstanding Basic | 1.6M | 1.2M | 20.0M | 818.2K | 791.2K | 15.5M | 13.0M | 12.2M | 11.6M | 11.1M | 10.3M | 10.2M | 10.1M | 7.0M | 6.9M | 6.3M | |
| Weighted Average Number Of Diluted Shares Outstanding | 1.6M | 1.2M | 20.0M | 818.2K | 791.2K | 15.5M | 13.0M | 12.2M | 11.6M | 11.1M | 10.3M | 10.2M | 10.1M | 7.0M | 6.9M | 6.3M | |
| Earnings Per Share Basic | $-1.23 | $-1.89 | $-0.11 | $-3.45 | $-5.21 | $-0.28 | $-0.24 | $-0.28 | $-0.25 | $-0.32 | $-0.26 | $-0.26 | $-0.46 | $-0.57 | $-0.21 | $-0.21 | |
| Common Stock Shares Authorized | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | |||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Common Stock Shares Outstanding | 1.8M | 1.5M | 22.4M | 16.8M | 16.0M | 15.8M | 13.0M | 13.0M | 11.7M | 11.6M | 10.3M | 10.3M | 10.1M | 9.9M | |||
| Common Stock Shares Issued | 1.8M | 1.5M | 22.4M | 16.8M | 16.0M | 15.8M | 13.0M | 13.0M | 11.7M | 11.6M | 10.3M | 10.3M | 10.1M | 9.9M | |||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 7.0M | 6.0M | |||||||||||||||
| Preferred Stock Shares Authorized | |||||||||||||||||
| Preferred Stock Par Or Stated Value Per Share |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Stock Issued During Period Value Issued For Services | $322.3K | $833.7K | $559.6K | $430.7K | $1.6M | $572.1K |
| Stock Granted During Period Value Sharebased Compensation | $3.2M | $2.9M | $5.2M | $695.8K | ||
| Share Based Payment To Vendors | $322.3K | $833.7K | $559.6K | $430.7K | $1.6M | $572.1K |
| Prepaid Expense Current | $85.0K | $100.1K | $105.8K | $265.0K | $295.3K | $48.6K |
| Stock Issued During Period Shares New Issues | 17.9K | |||||
| Additional Paid In Capital | $80.6M | $67.9M | $57.9M | $45.9M | $38.9M | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $1.2M | $2.6M | $3.2M | |||
| Stock Issued During Period Value New Issues | $3.7M | $14.8M | ||||
| Warrant Exercise Pre Funded Shares | 36.6K | 6.5K | ||||
| Sale Of Stock Consideration Received On Transaction | ||||||
| Warrant Exercise Pre Funded | $73.00 | $13.00 | ||||
| Stock Issued During Period Value Warrant Exercises | $1.4M | $210.2K | $2.2M | |||
| Stock Units Issued During Period Value Executive Compensation Settled | $916.8K | $781.7K | ||||
| Issuance Of Stock And Warrants For Services Or Claims | $916.8K | $781.7K | ||||
| Investment Income Interest | $125.4K | $20.1K | ||||
| Stock Issued During Period Shares Warrant Exercises | 422.1K | 59.2K | ||||
| Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction | $2.0M | |||||
| Stock Units Issued During Period Value New Issues | $4.4M | |||||
| Gain Loss On Forgiveness Of Paycheck Protection Program Loan Cares Act | $66.5K | |||||
| Warrant Inducement Financing Costs | $4.6M | |||||
| Proceeds Warrant Exercises Net2025 | $2.5M | |||||
| Paycheck Protection Program Loan Cares Act Noncurrent | $49.9K | |||||
| Paycheck Protection Program Loan Cares Act Current | $16.6K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Issued For Services | $45.1K | $86.2K | $110.1K | $121.4K | $213.5K | $305.6K | $165.9K | $127.1K | $188.1K | $1.3M | $37.5K | $135.5K | $131.6K | $161.1K | $181.1K | |||
| Stock Granted During Period Value Sharebased Compensation | $833.3K | $806.5K | $733.5K | $697.0K | $716.7K | $761.1K | $2.1M | $2.2M | $191.7K | $175.0K | $166.7K | $166.7K | ||||||
| Share Based Payment To Vendors | $110.1K | $305.6K | $165.9K | $188.1K | $135.5K | |||||||||||||
| Prepaid Expense Current | $158.2K | $53.5K | $161.6K | $122.8K | $168.4K | $187.9K | $105.7K | $89.9K | $206.6K | $337.8K | $116.9K | $239.5K | $530.6K | $344.5K | ||||
| Stock Issued During Period Shares New Issues | 601.9K | 1.2M | 2.9M | |||||||||||||||
| Additional Paid In Capital | $77.3M | $75.3M | $71.8M | $67.2M | $65.1M | $63.6M | $52.0M | $51.2M | $46.8M | $45.1M | $40.6M | $39.9M | $38.2M | $34.8M | ||||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $294.8K | $324.2K | $333.6K | $345.2K | $1.0M | $894.5K | $833.3K | $806.5K | $733.5K | |||||||||
| Stock Issued During Period Value New Issues | $1.6M | $320.2K | $4.3M | $3.5M | $3.7M | $14.8M | ||||||||||||
| Warrant Exercise Pre Funded Shares | ||||||||||||||||||
| Sale Of Stock Consideration Received On Transaction | $4.3M | $3.5M | $3.7M | |||||||||||||||
| Warrant Exercise Pre Funded | $73.00 | $13.00 | ||||||||||||||||
| Stock Issued During Period Value Warrant Exercises | $210.2K | |||||||||||||||||
| Stock Units Issued During Period Value Executive Compensation Settled | $916.8K | $781.7K | ||||||||||||||||
| Issuance Of Stock And Warrants For Services Or Claims | $916.8K | |||||||||||||||||
| Investment Income Interest | $35.9K | $23.4K | $5.0K | $782.00 | ||||||||||||||
| Stock Issued During Period Shares Warrant Exercises | 595.0K | |||||||||||||||||
| Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction | ||||||||||||||||||
| Stock Units Issued During Period Value New Issues | $1.7M | $455.0K | ||||||||||||||||
| Gain Loss On Forgiveness Of Paycheck Protection Program Loan Cares Act | $66.5K | |||||||||||||||||
| Warrant Inducement Financing Costs | ||||||||||||||||||
| Proceeds Warrant Exercises Net2025 | ||||||||||||||||||
| Paycheck Protection Program Loan Cares Act Noncurrent | ||||||||||||||||||
| Paycheck Protection Program Loan Cares Act Current |
Most recent annual filing with the SEC: March 12, 2026
Data sourced from SEC EDGAR public filings as of August 7, 2026.